Zacks Research Has Bullish Forecast for HALO FY2025 Earnings

Halozyme Therapeutics, Inc. (NASDAQ:HALO) – Stock analysts at Zacks Research increased their FY2025 EPS estimates for Halozyme Therapeutics in a research report issued on Tuesday, December 10th. Zacks Research analyst R. Department now expects that the biopharmaceutical company will earn $4.45 per share for the year, up from their previous estimate of $4.40. The consensus estimate for Halozyme Therapeutics’ current full-year earnings is $3.80 per share. Zacks Research also issued estimates for Halozyme Therapeutics’ Q3 2026 earnings at $1.44 EPS and FY2026 earnings at $5.84 EPS.

Several other analysts have also commented on the company. Piper Sandler increased their price objective on Halozyme Therapeutics from $51.00 to $52.00 and gave the company a “neutral” rating in a report on Monday, November 4th. Cowen reiterated a “buy” rating on shares of Halozyme Therapeutics in a research note on Friday, October 18th. JPMorgan Chase & Co. lowered Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and boosted their price target for the stock from $52.00 to $57.00 in a research note on Thursday, September 19th. HC Wainwright restated a “buy” rating and set a $68.00 price objective on shares of Halozyme Therapeutics in a report on Wednesday, November 20th. Finally, JMP Securities upped their price target on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a research note on Friday, November 1st. Four research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, Halozyme Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $61.11.

Halozyme Therapeutics Trading Up 0.4 %

NASDAQ HALO opened at $48.00 on Friday. The firm has a market cap of $6.11 billion, a PE ratio of 15.89, a price-to-earnings-growth ratio of 0.43 and a beta of 1.23. Halozyme Therapeutics has a 52 week low of $33.15 and a 52 week high of $65.53. The company has a quick ratio of 9.15, a current ratio of 10.36 and a debt-to-equity ratio of 3.32. The company has a 50 day moving average price of $51.43 and a 200 day moving average price of $53.92.

Institutional Investors Weigh In On Halozyme Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. International Assets Investment Management LLC acquired a new stake in Halozyme Therapeutics during the second quarter valued at $33,000. Skandinaviska Enskilda Banken AB publ acquired a new stake in shares of Halozyme Therapeutics during the 2nd quarter valued at about $49,000. GAMMA Investing LLC grew its position in shares of Halozyme Therapeutics by 67.7% during the 3rd quarter. GAMMA Investing LLC now owns 867 shares of the biopharmaceutical company’s stock valued at $50,000 after acquiring an additional 350 shares during the period. Toth Financial Advisory Corp purchased a new position in shares of Halozyme Therapeutics in the 3rd quarter valued at about $57,000. Finally, FSC Wealth Advisors LLC acquired a new position in Halozyme Therapeutics in the 3rd quarter worth about $65,000. Institutional investors and hedge funds own 97.79% of the company’s stock.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 18th. The stock was sold at an average price of $62.03, for a total value of $620,300.00. Following the completion of the transaction, the senior vice president now directly owns 173,756 shares of the company’s stock, valued at approximately $10,778,084.68. The trade was a 5.44 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Over the last three months, insiders have sold 40,000 shares of company stock valued at $2,242,100. 2.40% of the stock is owned by insiders.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.